1Mora J,Gerald W L,Qin J,et al.Evolving significance of prognostic markers associated with treatment improvement in patients with stage 4 neuroblastoma.Cancer (Phila.),2004; 94:2756-2765.
3Schmidt ML,Lal A,Seeger R,et al.Favorable prognosis for patients ages 12 - 18 months with stage 4 MYCN - nonamplified neuroblastoma [abstract].Proc Am Soc Clin Oncol,2003; 22:800.
4Ladenstein R,Ambros IM,Potschger U,et al.Prognostic significance of Dna di -tetraploidy in neuroblastona.Med Pediatr Oncol,2001; 36(1) :83 -92.
5Saito - Ohara F,Imoto I,Inoue J,et al.PPM1D is a potential target for 17q gain in neuroblastoma.Cancer Res,2003; 63:1876 -83.
6Bown N,Lastowska M,Cotterill S,et al.17q gain in neuroblastoma predicts adverse clinical outcome.U.K Cancer Cytogenetics Group and the U.K.Children's Cancer Study Group.Med Pediatr Oncol,2001 ;36(1) 14 - 19.
7Mihaila D,Aprodu G,Ionescu C,et al.Limitations in the his topathologic diagnosis and prognosis of neuroblastoma.Rev Med Chir Soc Med Nat Lasi,2003; 107(4) :834 -840.
8M Monsaingeon,G Simonnet,J - B Corcuff.Comparative values of catecholamines and metabolites for the diagnosis of neuroblastoma.Eur J Pediatr,2003; 162:397 -402.
9Departnent of Pathology,Yale University School of Medicine.Hormonal activity may predict aggressive behavior in neuroblastoma.Pediatric and Development Pathology,2002; 5:190 - 199.
10Thorner Ps,Squire JA.Mloecular genetics in the diagnosis and prognosis of solid pediatric tumors.Pediatr Dev Pathol,1998; 1:337- 365.
9Yang CP, Hung U, Aing TH, Chang WH. Cancers in infancy: percent distribution and incidence rates. Acta Paediatr Taiwan, 2006 Nov- Dec;47(6) :273-277.
10Gurney JG, Ross JA, Wall DA, BleyerWA, et, al. Infant cancer in the U. S: histology-specific incidence and trends, 1973 to 1992. J Pediatr Uematol Oncol, 1997 Sep-Oct ; 19 (5) :428-432.
